Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer
This is a pilot study looking at using stereotactic radiosurgery and full dose chemotherapy to treat stage II and III lung cancer that is not amendable to surgical resection.
Checked against the public recordLast updated Jan 31, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Early Phase 1
- Sponsor
- The Cooper Health System
- Interventions being studied
- Drug: Pemetrexed; Drug: Carboplatin; Drug: Cisplatin; Drug: Docetaxel; Drug: Paclitaxel; Radiation: stereotactic radiosurgery
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion criteria: * Nonsmall cell lung cancer (NSCLC) (any histology) * unresectable stage II * Stage III * Tumor less than 8 cm * Karnofsky performance scale (KPS) of 50 or better * Three or fewer mediastinal or hilar lymph nodes Exclusion criteria * Small cell lung cancer (SCLC) * Stage I and stage IV patients * Stage II patients eligible for surgical resection * Concurrent severe disease that the treating physician feels will interfere with therapy this can include significant cardiovascular or pulmonary disease. * KPS 40 or less (bed bound) * Tumor size greater than 8 cm * Inability to safely treat target lesions (at discretion of treating physician, this would most likely be secondary to not being able to place fiducial markers for tracking) * Four or more medisatinal or hilar lymph nodes
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- MD Anderson Cancer Center at CooperCamden, New Jersey
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 31, 2017. Always confirm current availability with the study team.